News | FFR Technologies | July 09, 2020

Acist Launches New Advance in FFR Microcatheters

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

July 9, 2020 – Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist Navvus II Rapid Exchange fractional flow reserve (FFR) microcatheter, the second-generation microcatheter for use with its Acist RXi Rapid Exchange FFR System.

FFR measurements provide assessment of arterial lesion severity and inform intervention strategy in both diagnosis and treatment of coronary artery disease. This latest advance delivers the same level of control, consistency and accuracy that physicians have come to expect from the original Navvus microcatheter, with valuable new enhancements. Specifically, the Acist Navvus II features a streamlined crossing contour, 28 percent more flexibility[1] and a lesion entry profile reduced by 15 percent.[2] The result is a highly deliverable microcatheter that may improve procedural efficiency.

The Navvus II Rapid Exchange MicroCatheter and its predecessor, Navvus, are the only coronary physiology products that allow the use of the physician’s 0.014 inch guidewire of choice. This market distinction may enable more efficient, faster diagnostic and post-PCI physiological assessment because wire position is maintained throughout the procedure.

Recently, the FFR-SEARCH study reported an average of 5 minutes per lesion to assess physiology following the intervention using the Acist microcatheter-based system.[3] FFR-SEARCH is a robust and independent, physician-sponsored study that utilized a prospective, all-comers registry and over 600 patients were analyzed.

“This latest advance represents the company’s continued strategic commitment to our market-defining FFR technology,” said Kristen Knox, SVP, general manager, Acist Medical Systems. “Physicians know they can rely on Navvus—and now Navvus II—to easily and quickly guide treatment decisions by invasive physiologic measurement.”

For more information https://acist.com/products/acist-rxi/navvusii-catheter/

 
References:

1. TR-07888: Compared with Navvus FFR MicroCatheter in benchtop testing. Data on file at ACIST. May not be indicative of clinical performance.

2. TR-08707: Compared with Navvus FFR MicroCatheter in benchtop testing. Data on file at ACIST. May not be indicative of clinical performance.

3. Rutger J. van Bommel, Kaneshka Masdjedi, Roberto Diletti, et al. Routine Fractional Flow Reserve Measurement After Percutaneous Coronary Intervention. The FFR-SEARCH Study. Circulation: Cardiovascular Interventions. 2019;12. Originally published 25 Apr 2019. https://doi.org/10.1161/CIRCINTERVENTIONS.118.007428. 2019;12

 

Related Content

Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.